GlassScriptPhysician profile
Mark J Gauthier
NPI 1629593355
$7,771.34
in general payments reported to CMS, 2019-2025
20 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,586 · 2022: $1,485 · 2023: $1,771 · 2024: $1,552 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,700.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,292.36 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $813.59 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $531.24 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $530.50 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $431.60 | 2021-2024 | Caplyta |
| Lundbeck LLC | $380.66 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $375.10 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $273.15 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $263.74 | 2021-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Axsome Therapeutics, INC. | $245.24 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $186.76 | 2021-2025 | Austedo Xr, Uzedy |
| Jazz Pharmaceuticals INC. | $94.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.90 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $78.90 | 2021-2023 | Trintellix |
| Corium, LLC | $67.07 | 2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.35 | 2021 | |
| Bausch Health US, LLC | $28.20 | 2021-2022 | |
| Indivior INC. | $28.17 | 2023-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $14.60 | 2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $13.30 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gauthier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.